{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-018383","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.577552+00:00","generated_at":"2026-06-21T08:55:49.584888+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas reports positive Phase 1/2 RUBY trial data for EDIT-301 in sickle cell disease","bullets":["First two patients engrafted successfully; no vaso-occlusive events after treatment with EDIT-301.","Patient 1 at 5 months post-treatment: total hemoglobin 16.4 g/dL, fetal hemoglobin 45.4%, HbF pancellular >95%.","EDIT-301 well-tolerated; safety profile consistent with myeloablative conditioning and autologous transplant.","First clinical use of proprietary AsCas12a nuclease to edit human cells; further data expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-018383","json":"https://secwatch.observer/filing/0001558370-22-018383.json","markdown":"https://secwatch.observer/filing/0001558370-22-018383.md","text":"https://secwatch.observer/filing/0001558370-22-018383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/0001558370-22-018383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/edit-20221206x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:55:49.584888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}